Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer
NCT ID: NCT05306041
Last Updated: 2025-02-17
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
170 participants
INTERVENTIONAL
2023-01-02
2027-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab and Pertuzumab for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer
NCT02131064
Pyrotinib Combined With Trastuzumab, Dalpiciclib, Letrozole Versus TCbHP (Trastuzumab Plus Pertuzumab With Docetaxel and Carboplatin) as Neoadjuvant Treatment in HR +/HER2 + Breast Cancer
NCT05638594
Efficacy and Safety Study of Trastuzumab and Paclitaxel Based Regimens to Treat HER2-positive Breast Cancer
NCT01428414
A Study of Pertuzumab in Combination With Herceptin and Chemotherapy in Participants With HER2-Positive Breast Cancer
NCT00976989
Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab in Patients With HER2 Positive Breast Cancer
NCT03588091
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
170 patients with confirmed eligibility criteria and PIK3CA mutant breast cancer will be randomized in a 1:1 ratio to receive: Neoadjuvant endocrine therapy in combination with dual anti-HER2 blockade consisting of ready-to-use fixed-dose combination of pertuzumab and trastuzumab as subcutaneous (PH-FDC SC) formulation q3w for 6 cycles (18 weeks) with (6cycles) or without inavolisib. Endocrine therapy consists of either tamoxifen 20mg or an aromatase inhibitor +/- GnRH analogue for premenopausal women and men.
In both study arms, treatment will be given until surgery/core-biopsy, disease progression, unacceptable toxicity, or withdrawal of consent of the patient.
All patients will undergo surgery or biopsy after completing study therapy to assess pCR rate.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Inavolisib
Inavolisib for 6 cycles (18 weeks) Neoadjuvant endocrine therapy in combination with dual anti-HER2 blockade consisting of ready-to-use fixed-dose combination of pertuzumab and trastuzumab as subcutaneous (PH-FDC SC) formulation q3w for 6 cycles (18 weeks)
Inavolisib
daily application of 9 mg (may be decreased to 6 mg and to 3 mg)
PHESGO
fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase s.c. (PH-FDC SC) q3w beginning on day 1 of cycle 1 for 6 cycles (18 weeks)
Endocrine therapy
Endocrine therapy per physician´s choice with either tamoxifen 20mg or an aromatase inhibitor +/- GnRH analogue for premenopausal women and men
without Inavolisib
Neoadjuvant endocrine therapy in combination with dual anti-HER2 blockade consisting of ready-to-use fixed-dose combination of pertuzumab and trastuzumab as subcutaneous (PH-FDC SC) formulation q3w for 6 cycles (18 weeks)
PHESGO
fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase s.c. (PH-FDC SC) q3w beginning on day 1 of cycle 1 for 6 cycles (18 weeks)
Endocrine therapy
Endocrine therapy per physician´s choice with either tamoxifen 20mg or an aromatase inhibitor +/- GnRH analogue for premenopausal women and men
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Inavolisib
daily application of 9 mg (may be decreased to 6 mg and to 3 mg)
PHESGO
fixed-dose combination of pertuzumab and trastuzumab with hyaluronidase s.c. (PH-FDC SC) q3w beginning on day 1 of cycle 1 for 6 cycles (18 weeks)
Endocrine therapy
Endocrine therapy per physician´s choice with either tamoxifen 20mg or an aromatase inhibitor +/- GnRH analogue for premenopausal women and men
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Untreated, unilateral primary carcinoma of the breast, confirmed histologically by core biopsy. Fine-needle aspiration alone is not sufficient. Incisional biopsy is not allowed.
3. Tumor lesion in the breast must be measurable in two dimensions, preferably by sonography.
4. Patients must be in the following stages of disease:
• cT1b - cT3 regardless of nodal status In patients with multifocal or multicentric breast cancer the largest lesion (target lesion) should be measured.
5. HR+/HER2+ disease with centrally confirmed ER-status, PR-status, HER2-status, PIK3CA mutation (tumor), Ki-67 value and TILs on core biopsy (target lesion). ER/PgR positive and HER2-positive is defined according to current ASCO/CAP guidelines. Formalin-fixed, paraffin-embedded (FFPE) breast tissue from core biopsy of target lesion has therefore to be sent to the GBG central pathology laboratory prior to randomization. In patients with multifocal or multicentric breast cancer, all non-target lesions must also be HR+/HER2+, as confirmed by local testing.
6. Age ≥ 18 years, female and male.
7. ECOG Performance status 0-1.
8. Normal cardiac function must be confirmed by ECG and cardiac ultrasound (LVEF or shortening fraction) within 3 months prior to randomization. Results for LVEF must be above 55%.
9. Laboratory requirements:
Hematology
* Absolute neutrophil count (ANC) ≥ 1.5/ nL
* Platelets ≥ 100/ nL and
* Hemoglobin ≥ 10 g/dL (≥ 6.2 mmol/L) Hepatic function
* Total bilirubin \< ULN except for patients with Gilbert's syndrome who may only be included if the total bilirubin is ≤ 3.0 × ULN or direct bilirubin ≤ 1.5 × ULN
* AST and ALT ≤ 1.5x ULN and
* Alkaline phosphatase ≤ 2.5x ULN
Glucose Metabolism:
• Glycosylated hemoglobin (HbA1c) \< 6.5%
10. Negative pregnancy test (urine or serum) within 14 days prior to randomization for all women of childbearing potential. A woman is considered to be of childbearing potential if she is not hysterectomized or not postmenopausal.
Postmenopausal is defined as:
* ≥12 continuous months of amenorrhea with no identified cause other than menopause.
* Having undergone bilateral oophorectomy.
11. For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use contraceptive methods that result in a failure rate of \< 1% per year during the treatment period and for least 7 months after the last dose of PH-FDC SC. Examples of non-hormonal contraceptive methods with a failure rate of \< 1% per year include: bilateral tubal ligation; male partner sterilization; intrauterine devices. For men: men must remain abstinent or use a condom with a spermicidal product during the treatment period and for 7 months after the last dose of PH-FDC therapy to avoid exposing the embryo. Men and women must refrain from donating sperm/eggs during this same period.
12. Staging work-up according to country guidelines prior to randomization including:
• Bilateral mammography and/or breast MRI in combination with a breast ultrasound. Exception: In men where MRI is medically not indicated breast ultrasound is sufficient.
13. Patient must be willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures.
Exclusion Criteria
2. Need of immediate neoadjuvant chemotherapy, e.g. inflammatory breast cancer.
3. Patients with definitive clinical or radiologic evidence of Stage IV cancer.
4. Excisional biopsy or lumpectomy and /or axillary lymph node dissection and/or sentinel lymph node biopsy performed prior to study entry (biopsy of clinical involved LN is warranted).
5. Prior chemotherapy or endocrine therapy or radiation therapy prior to study entry with the following exceptions:
• If medically indicated, initiation of endocrine therapy up to 28 days prior to randomization and use of established fertility preservation methods in young patients interested in subsequent pregnancies is allowed.
6. Patients with a history of breast cancer are ineligible with the following exceptions:
• Patient has been disease-free for more than 5 years and is at low risk for recurrence (at the investigator's discretion).
7. Patients with a history of any treated malignancy are ineligible in case of high risk of recurrence (at the investigator's discretion) and/or ongoing oncological treatment. This also applies to patients who are at high risk that oncological treatment is indicated during study therapy.
8. Patients with BMI\>30 can be included at the investigator's discretion.
9. Known hypersensitivity reaction to one of the compounds or substances, and/or murine proteins, and/or recombinant human hyaluronidase used in this protocol.
10. Patients with an established diagnosis of diabetes mellitus type I or uncontrolled type II based on FPG and HbA1c.
11. Patients who are immunocompromised as the result of HIV or receiving immunosuppressive therapies.
12. Clinically significant and active liver disease, for example, sclerosing cholangitis, active viral hepatitis B or C infection, or autoimmune hepatic disorders.
13. Patients with inflammatory bowel disease, such as Crohn's disease or ulcerative colitis, and active bowel inflammation (e.g., diverticulitis).
14. Patients with any concurrent ocular or intraocular condition, excluding baseline cataracts, that would require medical or surgical intervention during the study period to prevent or treat vision loss. In addition, patients with active uveitis or vitritis, history of uveitis, or active infectious process in the eye.
15. Patients with currently documented pneumonitis/interstitial lung disease.
16. Known or suspected congestive heart failure (\>NYHA I) and / or coronary heart disease, angina pectoris requiring antianginal medication, previous history of myocardial infarction, evidence of transmural infarction on ECG, uncontrolled or poorly controlled arterial hypertension (i.e. BP \>160 / 90 mm Hg under treatment with three antihypertensive drugs), rhythm abnormalities requiring permanent treatment, clinically significant valvular heart disease.
17. Damaged skin at planned site of subcutaneous (SC) injections (thigh).
18. Patients who may have had a recent episode of thromboembolism and are still trying to optimize the anticoagulation dose and/or have not normalized their INR.
19. Concurrent treatment with: • Chronic corticosteroids unless initiated \> 6 months prior to study entry and at low dose (10 mg or less methylprednisolone or equivalent).
* Sex hormones. Prior treatment must be stopped before randomization (GnRH a is allowed).
* Other experimental drugs or any other anti-cancer therapy.
20. Participation in another clinical trial with any investigational, not marketed drug within 30 days prior to study entry.
21. Female patients: pregnancy or lactation at the time of randomization.
22. History of significant neurological or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent.
23. Any condition that, in the opinion of the investigator, would interfere with evaluation of study treatment or interpretation of patient safety or study results.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Roche Pharma AG
INDUSTRY
GBG Forschungs GmbH
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Mattea Reinisch, PD Dr. med.
Role: PRINCIPAL_INVESTIGATOR
Universitätsmedizin Mannheim, Frauenklinik mit Brustzentrum
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
KEM Kliniken Essen-Mitte
Essen, North Rhine-Westphalia, Germany
Hämatologie-Onkologie im Zentrum MVZ GmbH
Augsburg, , Germany
DBZ Onkologie
Berlin, , Germany
Praxisklinik Krebsheilkunde für Frauen
Berlin, , Germany
Onkologische Schwerpunktpraxis Bielefeld
Bielefeld, , Germany
Department of Breast-Center Holweide - Kliniken der Stadt Köln
Cologne, , Germany
Städtisches Klinikum Dessau
Dessau, , Germany
University Hospital Carl Gustav Carus
Dresden, , Germany
Center for Gynecologic Oncology
Düsseldorf, , Germany
Frauenklinik des Universitätsklinikums Erlangen
Erlangen, , Germany
Klinik für Gynäkologie und Geburtshilfe Agaplesion Markus Krankenhaus
Frankfurt, , Germany
SRH Wald-Klinikum Gera GmbH
Gera, , Germany
Mammazentrum HH am Krankenhaus Jerusalem
Hamburg, , Germany
Klinikum Hanau
Hanau, , Germany
DIAKOVERE Henriettenstift Frauenklinik
Hanover, , Germany
National Center for Tumor Diseases - University Hospital Heidelberg
Heidelberg, , Germany
Elisabeth Krankenhaus Brustzentrum
Kassel, , Germany
Praxis für Hämatologie und Onkologie Koblenz and InVo - Institut für Versorgungsforschung in der Onkologie GbR
Koblenz, , Germany
University Hospital Mannheim
Mannheim, , Germany
University Hospital Gießen and Marburg, Campus Marburg
Marburg, , Germany
Media Vita GmbH (MVZ)
Münster, , Germany
University Hospital Tübingen
Tübingen, , Germany
Department of Gynecology and Obstetrics - University of Ulm
Ulm, , Germany
GRN Klinik Weinheim
Weinheim, , Germany
Klinikum Worms
Worms, , Germany
Helios Universitätsklinikum Wuppertal
Wuppertal, , Germany
Università Politecnica delle Marche - Azienda Ospedaliero Universitarià delle Marche
Ancona, , Italy
AULSS9 Scaligera - Ospedale Mater Salutis di Legnago
Legnago, , Italy
Istituto Europeo di Oncologica
Milan, , Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Johanna Frindte
Role: primary
Dr. med. Bernhard Heinrich
Role: primary
Dr. med. Antje Müller
Role: primary
Gülten Oskay-Özcelik
Role: primary
Dr. med. Siemke Steinke
Role: primary
Myriam Vincent
Role: primary
Dr. med. Hermann Voß
Role: primary
Dr. med. Theresa Link
Role: primary
Dr. med. Athina Kostara
Role: primary
Prof. Dr. med. MD Peter Fasching
Role: primary
Prof. Dr. med. Marc Thill
Role: primary
Dr. med. Dirk-Michael Zahm
Role: primary
Prof. Dr. med. Christian Schem
Role: primary
Dr. med. Jens Kosse
Role: primary
Dr. med. Kristina Lübbe
Role: primary
Prof. Dr. med. Andreas Schneeweiss
Role: primary
Dr. med. Sabine Schmatloch
Role: primary
Prof. Dr. med. Rudolf Weide
Role: primary
Priv. Doz. Dr. med. Mattea Reinisch
Role: primary
Dr. med. Niklas Gremke
Role: primary
Dr. med. Stefanie Wiebe
Role: primary
Prof. Dr. med. Andreas Hartkopf
Role: primary
PhD MD Brigitte Rack
Role: primary
Dr. med. Lelia-Eveline Bauer
Role: primary
Dr. med. Sebastian Züfle
Role: primary
Assoz. Prof. Priv.Doz. Dr. med. univ et scient. med., MBAVesna Bjelic-Radisic
Role: primary
Prof. Rossana Berardi
Role: primary
Dr. med. Anna Mercanti
Role: primary
MD Marco Colleoni
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
GBG105
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.